Last reviewed · How we verify
Standard-Dose Influenza Vaccine
Standard-dose influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.
Standard-dose influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Prevention of seasonal influenza in adults and children ≥6 months of age.
At a glance
| Generic name | Standard-Dose Influenza Vaccine |
|---|---|
| Sponsor | Tor Biering-Sørensen |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated influenza virus antigens (or live attenuated virus in some formulations) that trigger both humoral and cell-mediated immune responses. This priming of the adaptive immune system enables rapid recognition and neutralization of wild-type influenza virus upon natural exposure, reducing infection risk and disease severity.
Approved indications
- Prevention of seasonal influenza in adults and children ≥6 months of age
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults (PHASE3)
- CX-4945 in Viral Community Acquired Pneumonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard-Dose Influenza Vaccine CI brief — competitive landscape report
- Standard-Dose Influenza Vaccine updates RSS · CI watch RSS
- Tor Biering-Sørensen portfolio CI